BidaskClub upgraded shares of Endo International (NASDAQ:ENDP) (TSE:ENL) from a strong sell rating to a sell rating in a report released on Tuesday morning.
Other equities research analysts also recently issued reports about the company. Cantor Fitzgerald decreased their price objective on Endo International from $9.00 to $7.00 and set a neutral rating for the company in a report on Friday, November 10th. ValuEngine downgraded Endo International from a buy rating to a hold rating in a report on Friday, February 2nd. B. Riley assumed coverage on Endo International in a report on Wednesday, February 14th. They issued a buy rating and a $10.00 price objective for the company. Gabelli downgraded Endo International from a buy rating to a hold rating in a report on Wednesday, February 28th. Finally, Guggenheim assumed coverage on Endo International in a report on Tuesday, December 12th. They issued a neutral rating and a $8.50 price objective for the company. Three research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. Endo International has an average rating of Hold and a consensus price target of $10.27.
Shares of Endo International (ENDP) opened at $6.98 on Tuesday. The firm has a market capitalization of $1,580.00, a P/E ratio of -1.26 and a beta of 0.35. Endo International has a fifty-two week low of $5.77 and a fifty-two week high of $14.15. The company has a quick ratio of 0.85, a current ratio of 1.02 and a debt-to-equity ratio of 17.00.
A number of large investors have recently added to or reduced their stakes in ENDP. Paloma Partners Management Co purchased a new position in Endo International in the fourth quarter worth $122,000. Oakbrook Investments LLC purchased a new position in Endo International in the fourth quarter worth $133,000. LMR Partners LLP purchased a new position in Endo International in the third quarter worth $148,000. Xact Kapitalforvaltning AB purchased a new position in Endo International in the fourth quarter worth $157,000. Finally, Elkfork Partners LLC purchased a new position in Endo International in the fourth quarter worth $194,000. Hedge funds and other institutional investors own 95.84% of the company’s stock.
Endo International Company Profile
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.